Abstract 1639P
Background
Endoscopic fine needle biopsy (EUS-FNB) is an effective tissue sampling modality for diagnosing pancreatic cancer. Genomic sequencing is becoming essential with the emerging targeted therapies in pancreatic cancer. However, the feasibility of commercial comprehensive next-generation sequencing on tissue obtained from EUS-FNB is unknown. We aimed to examine the success rate of genomic sequencing utilizing tissue from EUS-FNB and correlate it with procedural characteristics.
Methods
We retrospectively reviewed a consecutive cohort of patients who underwent a diagnostic EUS-FNB during the workup of a pancreatic mass, over five years, at our institution. Genomic results, patient demographics, tumor characteristics, and technical aspects of the EUS-FNB were reviewed. The successful completion of sequencing was defined as the generation and reporting of DNA sequencing results.
Results
A total of 396 patients underwent endoscopic ultrasound with pancreatic mass biopsy as part of the routine diagnostic workup. Tumor sequencing from the pancreatic EUS-FNB was requested from 101 patient samples. The remaining samples had no sequencing performed, or sequencing was requested on pancreatectomy samples and/or metastatic sites. Of the 101 patients, sequencing was successful in 88 samples (87%). The median number of needle passes to obtain sufficient tissue for completion of sequencing was 3 (range 1-5). Tumor purity information was available in 71 samples; the average purity was 32% (range 20-90%). Genomic sequencing was unsuccessful in the remaining 13 samples (13%) due to inadequate tissue. The median number of needle passes for these patients was 2 (range 1-5). The cancer stage distribution for patients whose tumor sequencing was requested from pancreatic biopsies was the following: I (9%), II (10%), III (14%), and IV (67%). Genomic sequencing results will be presented at the meeting.
Conclusions
Comprehensive genomic sequencing of all stages of pancreatic cancer is feasible on EUS-FNB. Increasing the number of needle passes can increase the yield for tumor genomic sequencing. This is particularly important for locally advanced, unresectable pancreatic cancers without alternative sites for tissue sampling.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
V. Florou: Financial Interests, Personal, Advisory Role: Deciphera, Incyte. H.P. Soares: Financial Interests, Personal, Advisory Board: TerSera, Ipsen, AstraZeneca, Novartis, ITM. I. Garrido-Laguna: Financial Interests, Personal, Advisory Role: Sotio, Kanaph, Jazz, OncXerna. All other authors have declared no conflicts of interest.
Resources from the same session
1677P - Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma
Presenter: Daniele Lavacchi
Session: Poster session 22
1678P - A retrospective real-world study of nimotuzumab combined with chemotherapy for first-line treatment of advanced pancreatic cancer: A single center propensity score matched analysis
Presenter: Yinying Wu
Session: Poster session 22
1679P - Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: A systematic review and network meta-analysis
Presenter: Luca Mastrantoni
Session: Poster session 22
1680P - Meta-analysis of real-world survival outcomes of liposomal irinotecan in advanced pancreatic cancer patients with prior irinotecan exposure
Presenter: Amol Gupta
Session: Poster session 22
1681P - A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer
Presenter: Siyi Zou
Session: Poster session 22
1682P - Impact of metastatic site on survival in patients with synchronous metastatic pancreatic adenocarcinoma (PDAC): A national prospective BACAP study
Presenter: Emily Alouani
Session: Poster session 22
1683TiP - Trial in progress: NEO-adjuvant chemo-IMmunotherapy in PAnCreaTic cancer-NEO-IMPACT
Presenter: Sarah Maloney
Session: Poster session 22
1684TiP - PARPiPANC: A multicentric, single arm, phase II assessing niraparib as first line therapy for patients with metastatic homologous repair-deficient pancreatic cancer
Presenter: Philippe Cassier
Session: Poster session 22
1685TiP - Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): A multicenter randomized controlled trial
Presenter: Jacob van Dam
Session: Poster session 22
1686TiP - Olaparib and durvalumab (MEDI4736) phase II study in patients with metastatic pancreatic cancer and DNA damage repair genes alterations
Presenter: Teresa Macarulla
Session: Poster session 22